|
| Animal model | L-DOPA treatment | Biochemical 5-HT indexes | % of change | Reference |
|
| [3H]-5-HT preloaded rat | 10 μM | [3H]-5-HT release | +60% | [25, 29, 30] |
| midbrain slices | | | | |
| naive rats | intra-SNr 5 μM | ext 5-HT: STR and SNr | +55% in STR | [71] |
| | | +102% in SNr |
| 6-OHDA rats | 3, 6, 12, 100 mg/kg/d ip | ext 5-HT: STR, SNr, HIPP, PFC | 3: ∅ | |
| | | 6: STR/PFC ∅, SNr −22%, |
[31] + unpublished observations |
| HIPP −27% |
| 12: STR/HIPP ∅, SNr −17%, |
| PFC −27% |
| 100: STR/SNr/HIPP ∅, PFC −28% |
| | tiss 5-HT: STR | 3–12: ∅ | [31] |
| | | 100:−73% |
| 6-OHDA rats | 12 mg/kg/d ip 14 d | ext 5-HT and 5-HIAA: STR, SNr, HIPP, | 5-HT: STR −39%, SNr −45%, | [45] |
| | PFC | HIPP −29%, PFC –47% |
| 5-HIAA: STR −32%, SNr −58%, |
| HIPP −44%, PFC −51% |
| | tiss 5-HT and 5-HIAA: STR and CX | 5-HT: STR −48%, CX −63%, | |
| | | 5-HIAA: STR −67%,
CX −73% | |
| 6-OHDA rats | 6 mg/kg/d ip 14 d | ext 5-HT and 5-HIAA: STR and SNr | 5-HT: STR-LID +125%, | |
| | | STR-LND +75%; SNr-LID +104%,
SNr-LND +108%
5-HIAA: STR-LID −30%,
STR-LND −73%; SNr-LID −28%, SNr-LND −37% | [48] |
| | tiss 5-HT and 5-HIAA: STR and SNr | 5-HT: STR-LID −32%, |
| STR-LND −78% |
| 5-HIAA: STR-LND −76% |
| 6-OHDA rats | 6 mg/kg/d ip 14 d | tiss 5-HT: STR | −48% | [61] |
| 6-OHDA rats | 6 mg/kg/d ip 21 d | tiss 5-HT: STR | +150% | [72] |
|
| Animal model | L-DOPA treatment | Morphological 5-HT indexes | % of change | Reference |
|
| 6-OHDA rats | 5 mg/kg/d ip 14 d | SERT immunoreactivity: STR | +266% | [73] |
| 6-OHDA rats | 6 mg/kg/d ip 21 d | 5-HT immunoreactivity: STR | +70% in STR-LID | |
| | | ∅ in STR-LND | [74] |
| 6-OHDA rats | 6 and 50 mg/kg/d ip 14–21 d | SERT-binding density: STR and CX | 6: STR +37.5%, CX +75% | |
| | | 50: STR +87.5%, CX +125% | |
| | 5-HT immunoreactivity: number of | 6: +125% | |
| | varicosities, STR | 50: +200% | [55] |
| | 5-HT immunoreactivity: synapse | 6: +155% | |
| | incidence in STR | | |
| MPTP monkeys | Modopar (4 : 1) 15–20 mg/kg po | SERT-binding density: PUT and GP | PUT-LID +72%, GP-LID +400%, LND ∅ | |
| 6–8 m | | | [55] |
| MPTP monkeys | 12.5 mg/kg/d po 1 m | TPH immunoreactivity: STR and GP | STR: increased number and size of varicosities and |
| | | enlargement |
| | | GP: enlargement in GPi/e + increased number of varicosities and length of fibres in GPe | [56] |
|
| Animal model | L-DOPA treatment | Molecular 5-HT indexes | % of change | Reference |
|
| 6-OHDA mice and rats | (1) mice: 50 mg/kg/d ip 28 d | 5-HT1BR binding: STR, GP and SNr | (1) STR +20%, GP ∅, SNr +30% | |
| (2) rat: 100 mg/kg 2×d ip 5 d
(3) rat: 10 mg/kg/d ip 28 d | | (2) STR +17%, GP +38%, SNr + 61%
(3) STR +25%, GP ∅, SNr +55% | [75] |
| 6-OHDA rats | 100 mg/kg 2×d ip 5 d | 5-HT1BR protein: STR | +33% | [75] |
| 6-OHDA rats | 100 mg/kg 2×d ip 5 d | 5-HT2AR mRNA: STR | −57% | |
| | 5-HT2CR mRNA: STR and STN | ∅ | [76] |
| MPTP monkeys | Modopar | 5-HT1AR-binding: STR, premotor-motor | acute: ∅ | |
| acute: 14.6 mg/kg po | CX, HIPP | chronic: +140% in Caud matrix | [77] |
| chronic: 14.6 mg/kg 2×d po 120 d | | | |
| MPTP monkeys | Prolopa 100/25 mg/kg po 1 m | 5-HT2AR binding: STR and PFC | +58% in DM Caud | [78] |
| PD patients (LIDs) | | 5-HT2CR binding: SNr | +108% | [79, 80] |
|
